Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)

NCT06984328 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT06984328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06984328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)
Lead sponsor
Genmab
Phase
Phase 2
Overall status
Terminated
Start date
July 25, 2025
Completion date
May 15, 2026
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, metastatic cutaneous melanoma (stage iv), relapsed/refractory, locally advanced unresectable melanoma (stage iiib, iiic, or iiid)